Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples